Form 4: Director Kamil Ali-Jackson Receives Rigel Stock Grant

Rigel Pharmaceuticals director Kamil Ali-Jackson was granted 5,750 restricted stock units as part of board compensation.

Summary

• Director Kamil Ali-Jackson acquired 5,750 shares of Rigel Pharmaceuticals (RIGL) common stock.
• The acquisition occurred on May 15, 2026, via a restricted stock unit (RSU) award.
• The shares were granted at a price of $0 per share.
• Following this transaction, the director's total beneficial ownership stands at 15,125 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• The director's increased equity stake aligns their interests with those of shareholders.

Negatives

• None identified.

Risks

• Vesting of the RSU award is contingent upon the director's continuous service on the Board of Directors until the date prior to the next Annual Meeting.

Future Outlook

The RSU award will fully vest on the date prior to the company's next Annual Meeting, provided the director maintains continuous service.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure long-term alignment between directors and corporate performance.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard corporate governance practices for mid-cap biotechnology firms.

Stakeholder Impact

• Shareholders benefit from director alignment through equity ownership.

Next Steps

• Vesting of the 5,750 RSUs prior to the next Annual Meeting.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Trading, Director Compensation, Equity Grant